[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598665":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":38,"centralContacts":42,"locations":47,"responsibleParty":77,"collaborators":79,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":30,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":30,"enrollmentInfo":93,"targetDuration":30,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":70,"whyStopped":30,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"First Affiliated Hospital of Guangxi Medical University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Praziquantel","ACTIVE_COMPARATOR","Praziquantel tablets: Administer orally at 25 mg\u002Fkg per dose, three times daily (TID) for 2 consecutive days. The dose will be adjusted based on the participant's body weight. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet according to the physician's recommendation.",[13],"Drug: praziquantel",{"label":15,"type":16,"description":17,"interventionNames":18},"Albendazole","EXPERIMENTAL","Albendazole tablets: Administer orally at 10 mg\u002Fkg\u002Fday for 7 consecutive days. The daily dose will be administered in two divided doses. The dose will be adjusted based on the participant's body weight. If the calculated dose results in a non-integer number of tablets, the actual dose may be adjusted to the nearest whole tablet. The specific dose will be adjusted according to the physician's recommendation.",[19],"Drug: Albendazole",{"label":21,"type":16,"description":22,"interventionNames":23},"Tribendimidine","Tribendimidine enteric-coated tablets: Administer orally at 0.4 g once daily (QD) for 3 consecutive days.",[24],"Drug: Tribendimidine",[26,31,34],{"type":27,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Participants receive albendazole tablets orally at a total daily dose of 10 mg\u002Fkg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.",[15],null,{"type":27,"name":21,"description":32,"armGroupLabels":33,"otherNames":30},"Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.",[21],{"type":27,"name":35,"description":36,"armGroupLabels":37,"otherNames":30},"praziquantel","Participants receive praziquantel tablets orally at 25 mg\u002Fkg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.",[9],[39],{"name":40,"affiliation":5,"role":41},"Hongliang Zhang","PRINCIPAL_INVESTIGATOR",[43],{"name":40,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","+86 13737143253","277749097@qq.com",[48,68],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"People's Hospital of Guangxi Zhuang Autonomous Region","NOT_YET_RECRUITING","Nanning","Guangxi","530021","China","CN",{"type":57,"coordinates":58},"Point",[59,60],108.31667,22.81667,{"lat":60,"lon":59},[63,67],{"name":64,"role":44,"phone":65,"phoneExt":30,"email":66},"Li Zhang","+86 18577841728","30173359@qq.com",{"name":64,"role":41,"phone":30,"phoneExt":30,"email":30},{"facility":69,"status":70,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"The First Affiliated Hospital of Guangxi Medical University","RECRUITING",{"type":57,"coordinates":72},[59,60],{"lat":60,"lon":59},[75,76],{"name":40,"role":44,"phone":45,"phoneExt":30,"email":46},{"name":40,"role":41,"phone":30,"phoneExt":30,"email":30},{"type":78,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[80,81],{"name":49,"class":6},{"name":82,"class":83},"Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control","OTHER_GOV","100598665","phase-4-treatment-of-clonorchiasis-in-guangxi-with-albendazole-tribendimidine-and-praziquantel-100598665",false,"NCT07074444","Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel","Albendazole, Tribendimidine, and Praziquantel for Clonorchiasis in Guangxi: A Randomized Controlled Trial Comparing Efficacy and Safety","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Confirmed diagnosis of Clonorchis sinensis infection based on the latest Expert Consensus on Diagnosis and Treatment of Food-Borne Parasitic Diseases (2023): detection of eggs or adult worms in stool or bile drainage fluid.\n3. Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or allergy to albendazole, praziquantel, or tribendimidine.\n2. Electrocardiogram (ECG)-confirmed supraventricular tachycardia or atrial fibrillation.\n3. Clinically or radiologically diagnosed neurocysticercosis (brain or spinal cord) or ocular cysticercosis (eye or orbit).\n4. Presence of gallbladder stones or biliary tract obstruction as confirmed by abdominal ultrasound.\n5. Individuals with severe hepatic, renal, or cardiac dysfunction, or with active peptic ulcer disease.\n6. Pregnant or breastfeeding individuals, or those of reproductive potential (male or female) who are unwilling to use effective contraception during the study period and for 3 months following the last dose of study medication.\n7. Anticipated loss to follow-up due to relocation, withdrawal of consent, or other factors affecting adherence to the study protocol.","ALL","18 Years",{"count":94,"type":95},318,"ESTIMATED","INTERVENTIONAL",[98],"PHASE4","The goal of this clinical trial is to evaluate and compare the efficacy and safety of three commonly used antiparasitic drugs-albendazole, tribendimidine, and praziquantel-for the treatment of clonorchiasis, a liver fluke infection acquired by consuming raw or undercooked freshwater fish.\n\nThis study aims to answer the following primary questions:\n\nHow effective is each drug in achieving parasitological cure, as measured by clearance of Clonorchis sinensis eggs in stool? What types and frequencies of adverse events are associated with each treatment?\n\nParticipants in this randomized, open-label trial will:\n\nBe randomly assigned to receive one of the three study drugs according to a predefined dosing regimen.\n\nProvide stool samples before treatment and at follow-up to assess for Clonorchis sinensis eggs.\n\nUndergo a second round of the same treatment regimen and repeated stool examination if eggs are still detected after the first course.\n\nAttend follow-up visits, which include symptom assessment, blood tests (hematology and liver function), and abdominal ultrasonography focusing on hepatobiliary changes.\n\nReport any side effects, discomfort, or adverse reactions experienced during or after treatment.\n\nThe findings from this study will help inform optimal therapeutic strategies for clonorchiasis in outpatient clinical settings.",[101],"Clonorchiasis",[101,15,9,103,104],"Egg clearance rate","tribendimidine","2025-08-13",{"date":107,"type":108},"2025-08-17","ACTUAL",{"date":110,"type":108},"2025-07-22",{"date":112,"type":95},"2026-12-31",{"name":5,"class":6},2]